Symptoms can include itching, dryness, bumps, rash, blisters, or swelling. Contact dermatitis can occur on any part of the body, including the elbows. There are two broad categories of contact ...

Doctors are urging people not to ignore the symptoms of scabies because of the perceived social stigma attached to having the condition as cases rise in England. Some 3,689 cases of the highly ...

Cases of highly infectious skin bug scabies are surging across the UK, with cases occurring 'out of nowhere' and whole households affected. The condition, caused by microscopic mites that burrow ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

People are being told not to ignore an itchy rash, with GPs in England reporting a spike in scabies - the highly infectious skin infestation. The condition is caused by a mite which burrows under ...

Scabies can lead to secondary skin infections, if not treated. People are being told not to ignore an itchy rash, with GPs in England reporting a spike in scabies - the highly infectious skin ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for breast cancer, providing a boost to Novartis' (NOVN: VX) Kisqali (ribociclib). The new guidelines make ...

Kisqali ® (ribociclib) is a selective cyclin-dependent kinase ... Tell your health care provider or get medical help right away if you get severe rash or rash that keeps getting worse; reddened skin; ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...

EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...